4D Molecular Therapeutics, Inc. (FDMT)

Over the past six months, FDMT's stock experienced a 52-week low of $2.25 and a high of $12.34, closing at $9.31 on February 4, 2026. The company announced positive interim clinical data for 4D-710 in December 2025 and provided a company update in January 2026. A significant partnership was secured in 2025, contributing to a revenue surge. A workforce reduction was implemented to conserve cash. Short interest in the stock recently increased.

The demand for 4D Molecular Therapeutics' products and services is not typically subject to seasonal fluctuations. Demand is driven by medical need and the progression of clinical trials and regulatory approvals.

4D Molecular Therapeutics, Inc. (FDMT) is a biotechnology company focused on developing genetic medicines for ophthalmology, pulmonology, and cardiology. They use their Therapeutic Vector Evolution platform to engineer AAV vectors for improved gene delivery. Key product candidates include 4D-150 for retinal vascular diseases (Phase 3), 4D-710 for cystic fibrosis (early-stage), 4D-175 for geographic atrophy (preclinical), 4D-725 for alpha-1 anti-trypsin deficiency lung disease (preclinical), and 4D-310 for Fabry disease (Phase 1). The company was founded in 2013 and is headquartered in Emeryville, California.

4D Molecular Therapeutics is headquartered in Emeryville, California. Its development activities are conducted in the Netherlands and the United States.

4D Molecular Therapeutics has generally maintained a positive reputation among analysts, with a consensus rating of "Buy" or "Moderate Buy" and an average rating score of 2.70. The median price target is $33.00. Positive clinical data from the 4D-710 trial and a significant licensing deal have likely enhanced its reputation. A workforce reduction and increased short interest could be viewed with mixed sentiment.

Approximately 78.22% of 4D Molecular Therapeutics' shares are held by institutional owners. Institutional shareholders own 69.20% of the company, while insiders own 22.28%, and retail investors hold 8.52%. Major institutional owners include BVF Inc/il, RA Capital Management, L.P., Goldman Sachs Group Inc, BlackRock, Inc., Vanguard Group Inc, Novo Holdings A/S, and Janus Henderson Group Plc. David Kirn, Co-Founder, President, CEO & Director, holds 2.90% of the shares.